Prometheus Biosciences, Inc.

Financial performance has remained strong, with revenue growing from $1.27M in Q4 2022 to $1.10M in Q3 2023. Gross profit continued to perform well, with margins at 100% in the latest quarter. Operating income reached -$48.70M in Q3 2023, holding a steady -4408% margin. While R&D and SG&A expenses fluctuated, EBITDA remained robust at -$48.70M. Net income dropped to -$40.88M, keeping EPS at -$0.86. With disciplined cost control and operational efficiency, the company supported consistent profitability, reflecting its ability to deliver stable shareholder value.